Ignite Creation Date:
2024-05-05 @ 11:35 AM
Last Modification Date:
2024-10-26 @ 9:10 AM
Study NCT ID:
NCT00089648
Status:
COMPLETED
Last Update Posted:
2010-01-12
First Post:
2004-08-09
Brief Title:
SU011248 In The Treatment Of Patients With Bevacizumab Avastin-Refractory Metastatic Renal Cell Carcinoma
Sponsor:
Pfizer
Organization:
Pfizer
Study Overview
Official Title:
A Phase 2 Study Of SU011248 In The Treatment Of Patients With Bevacizumab-Refractory Metastatic Renal Cell Carcinoma
Status:
COMPLETED
Status Verified Date:
2010-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to test whether sunitinib SU011248 has activity and is safe in patients with renal cell carcinoma RCC who have failed prior therapy with bevacizumab Avastin -based treatment
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None